10 November 2017

2nd SCI/RSC Fibrosis Medicinal Chemistry Symposium

Organised by:

SCI's Fine Chemicals Group and RSC's Biological and Medicinal Chemistry Sector

London, UK

Registration Closed

This event is no longer available for registration.

Synopsis

Fibrosis disease can manifest in many areas of the body, the result of a disregulated wound healing process after injury, which can lead to high mortality. With two drugs recently reaching marketed status for IPF (Idiopathic Pulmonary Fibrosis), there is continued growth and investment to identify new treatments, including for other conditions such as liver fibrosis and diabetic nephropathy. Fibrosis has complex disease pathology and greater knowledge of mechanisms is sought. This symposium will cover drug discovery and medicinal chemistry aspects of fibrotic conditions from leading experts in the field.

Attendees

The conference will be of interest to researchers, academics, students and industrialists with an interest in fibrosis disease, medicinal chemistry and drug discovery.

Programme

Day 1 - 10 November 2017

09:00: Registration and refreshements
10:00: Opening remarks
10:05: An overview of liver and kidney fibrosis Dr Fiona Oakley, University of Newcastle, UK
10:50: Idiopathic pulmonary fibrosis: Impact of current treatments, limitations and opportunities Dr Hannah Woodcock, University College London, UK
11:25: Refreshments
11:45: Discovery and development of galectin-3 ligand mimetics as anti-fibrosis compounds Prof Ulf Nilsson, Lund University, Sweden
12:20: αv integrin modulators for fibrosis and the profile of an αvβ6 clinical candidate Dr Simon Macdonald, GlaxoSmithKline, UK
13:00: Lunch
14:00: Discovery of GLPG1690: a first-in-class autotoxin inhibitor in clinical development for the treatment of idiopathic pulmonary fibrosis Dr Nicolas Desroy, Galapagos, France
14:35: Porcupine inhibitors as anti-fibrotic therapies Dr Cliff Jones, Redx Pharma Plc, UK
15:10: Refreshments
15:40: Cannabinoid Receptor (CB1R) based dual-target approaches for the treatment of fibrotic conditions Dr Malliga Iyer, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, USA
16:15: Transglutaminase 2: an ideal therapeutic target for the treatment of fibrosis using small molecule inhibitors Prof Martin Griffin, School of Life & Health Sciences, Aston University, UK
16:50: Closing remarks
16:55: Close

Venue and Contact

SCI

14/15 Belgrave Square
London
SW1X 8PS

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

Fees

Early bird fees before Friday 29 September 2017

GB£80 . . . . . . . . . . . . . . . . . SCI/RSC Member
GB£35 . . . . . . . . . . . . . . . . . SCI/RSC Student Member
GB£50 . . . . . . . . . . . . . . . . . SCI/RSC Subsidised Member
GB£120 . . . . . . . . . . . . . . . ..Non-Member

Standard fees after Friday 29 September 2017

GB£110 . . . . . . . . . . . . . . . . . SCI/RSC Member
GB£50 . . . . . . . . . . . . . . . . . . SCI/RSC Student Member
GB£75 . . . . . . . . . . . . . . . . . . SCI/RSC Subsidised Member
GB£150 . . . . . . . . . . . . . . . . . Non-Member

SCI Platinum Corporate Members receive 25% off the above rates.

Become an SCI Member and save on this and future events

See Membership Options

Booking Process/Deadlines

For booking terms and conditions click here.

CPD Info

SCI Members attending this meeting are able to claim CPD points.

Partners

Additional Info

Call for Papers

Interested applicants should send a maximum one A4 page or 300 words indicating title, authors and preference for presentation option (Oral, Flash or Poster) to conferences@soci.org by Monday 30 October 2017 with the subject line "Fibrosis Medicinal Chemistry Symposium - abstract submission". Oral presentation slots are inevitably limited and will be allocated to achieve a balanced programme. The topics will need to have medicinal chemistry element to it where results, reviews or plans may have already been presented elsewhere. An abstract template can be downloaded here.

Bursaries

There are a limited number of bursaries available. Priority will be given to those presenting a poster. Please specify when sending in your abstract if you would like to be considered.

Organising Committee

Dr Simon Peace, SCI/ GlaxoSmithKline
Dr Daniel Hamza, SCI/ Sygnature Discovery
Dr Richard Hatley, BMCS/GlaxoSmithKline
Dr Mihiro Sunose, BMCS/Sygnature Discovery
Dr Fabien Lecomte, BMCS/UCB Pharma

Exhibition and Sponsorship

An exhibition will take place alongside the conference during refreshment breaks for companies and related organisations who may wish to exhibit. For further information and prices, please email conferences@soci.org. Spaces are limited and will be allocated on a first come, first served basis.